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To eliminate superfluous or damaged
cells, multicellular organisms have
evolved an efficient cell suicide mecha-
nism involving dedicated caspases that
cleave multiple intracellular proteins.
The major switch for their activation is
controlled by opposing factions of the
Bcl-2 family (Cory and Adams, 2002).
Whereas Bcl-2 and its closest relatives
(Bcl-xL, Bcl-w, A1, and Mcl-1) promote
cell survival, the structurally similar Bax
and Bak instead promote cell death
(Figure 1A). The life-death switch is
flipped by distant cousins (e.g., Bim,
Bad, Bid, Puma, and Noxa) that share
only the signature pro-death BH3 (Bcl-2
homology region 3) domain. Once these
“BH3-only” proteins are unleashed by
diverse intracellular stress signals, their
BH3 domain docks to an extended
hydrophobic groove on the pro-life Bcl-
2-like proteins (Liu et al., 2003; Sattler et
al., 1997), thereby neutralizing them. By
a poorly understood mechanism (see
below), this leads to aggregation of Bax
and Bak on the endoplasmic reticulum
and mitochondrial membranes, promot-
ing release of apoptogenic proteins
such as cytochrome c to trigger caspase
activation.
In many tumors, Bcl-2 or other pro-
life relatives are often overexpressed, or
signaling via BH3-only proteins is
impaired, typically due to mutation of the
p53 tumor suppressor, which would oth-
erwise induce Puma and Noxa to trigger
apoptosis (Villunger et al., 2003).
Nevertheless, nearly all tumors retain
the core apoptotic machinery. Therefore,
small molecules that directly target the
Bcl-2-like proteins by mimicking the BH3
domain (Figure 1A) should be highly
effective anticancer drugs (Cory and
Adams, 2002). One promising approach
is to create stabilized forms of BH3 pep-
tides (Walensky et al., 2004). An alterna-
tive route is to screen for small organic
molecules that supplant BH3 function.
Due to the challenge of targeting protein-
protein interactions, however, only candi-
dates with low affinity (µM versus the nM
binding of BH3 peptides) have previously
emerged, and the evidence that they act
as BH3 mimetics remains poor.
Now, however, Oltersdorf and col-
leagues have developed a very promis-
ing small molecule BH3 mimetic by using
a structure-based approach to target the
groove on Bcl-xL (Oltersdorf et al., 2005).
An initial high-throughput NMR-based
screen of a chemical library revealed two
leads that bound its groove at different
nearby sites, precisely where conserved
BH3 residues dock (Figure 1B). Guided
by the topography of the Bcl-xL groove,
these low affinity (mM) leads were then
bridged to form a much higher affinity (36
nM) derivative. Further modifications
minimized binding to human serum albu-
min and improved affinity for Bcl-xL and
Bcl-2. The final compound, ABT-737
(Figure 1C), binds Bcl-xL, Bcl-2, and Bcl-
w with high affinity (low or even sub nM),
even in 10% human serum, but has far
lower affinity for the more divergent 
Mcl-1 and A1.
Significantly, ABT-737 was cytotoxic
to B lymphoid tumor cell lines and prima-
ry cells from human follicular lym-
phomas. This probably reflects its
binding to Bcl-2-like proteins, because
the control enantiomer, which binds very
poorly, had ?30-fold lower activity.
Notably, ABT-737 also kills cells from
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Impairment of apoptosis, the physiologic cell death process, is central to cancer development and renders tumors refrac-
tory to cytotoxic therapy. Bcl-2, the oncoprotein activated in follicular lymphoma, inhibits the conserved cell death pathway
triggered by diverse cytotoxic agents, as do several close relatives. A small-molecule antagonist of these proteins has now
been designed by Oltersdorf et al. Strikingly, ABT-737 sensitizes many tumors to cytotoxic agents and is effective as a sin-
gle agent against certain lymphomas and solid tumors, provoking stable regression in some tumor xenografts. Hence, this
work validates Bcl-2-like proteins as important new targets in cancer therapy.
Figure 1. Targeting Bcl-2-like proteins to kill cancer cells
A: A BH3 mimetic such as ABT-737 engages the groove of a Bcl-2-like
protein, freeing Bax or Bak to trigger membrane permeabilization and
caspase activation. The inactivation of p53 function in most tumors
precludes induction of its targets, such as the genes encoding the
BH3-only proteins Noxa and Puma, which mediate its proapoptotic
function. Even tumors with the p53 pathway inactive should be vul-
nerable to the appropriate BH3 mimetic.
B: Small precursors of ABT-737 bind like a BH3 domain to the groove of
Bcl-xL. The two lead compounds that led to ABT-737 (carbon back-
bone, blue; oxygen, red; fluorine, green) are superimposed with the
Bim BH3 α-helix (mauve) on the surface of Bcl-xL (gray). Four con-
served BH3 amino acid residues critical for binding to Bcl-xL are shown:
leucine-94 (yellow), isoleucine-97 (yellow), aspartate-99 (orange),
and phenylalanine-101 (yellow). The drug leads mimic the BH3
domain at the three hydrophobic (yellow) residues, binding to
hydrophobic pockets on Bcl-xL, and have an acidic moiety (red) that,
like the aspartate, pairs with an essential arginine (Arg-139) in Bcl-xL.
The figure was adapted by Drs. Brian Smith and Peter Colman from
the structures of Oltersdorf et al. (2005) and Liu et al. (2003) with per-
mission.
C: Structure of ABT-737 (Oltersdorf et al., 2005).
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most (13 of 15) chronic lymphocytic
leukemias and most cell lines from small
cell lung cancers (SCLC).
The drug also yielded very impres-
sive results in vivo. Mice tolerated daily
injections for three weeks with no
adverse signs except a decline in
platelets and lymphocytes. When scid
mice implanted with a human follicular
lymphoma cell line were treated with
ABT-737, morbidity was delayed. Most
strikingly, two different SCLC xenografts
completely regressed in 77% of treated
mice and did not grow back when treat-
ment was stopped (monitoring continued
for 58 to 107 days). Caspase activity
assays suggested that the tumors
regressed due to apoptosis.
Many cell lines derived from solid
tumors resisted ABT-737 therapy. Never-
theless, ABT-737 markedly enhanced
(2–20 fold) their response to radiation
and a range of chemotherapeutic drugs
with different modes of action (etoposide,
doxorubicin, cisplatin, paclitaxel). Thus,
combination therapy with ABT-737 may
render such agents more effective at
lower doses, reducing collateral damage
to normal cells, or ensure more stable
remissions with conventional doses.
In binding profile, ABT-737 resem-
bles the BH3-only protein Bad. Whereas
certain potent BH3-only proteins,
notably Bid and Bim, have a BH3
domain that can provoke Bax/Bak-
dependent permeabilization of mito-
chondria and synthetic liposomes, Bad
and several others are relatively ineffec-
tual by themselves, but enhance the
potency of the first group (Kuwana et al.,
2005; Letai et al., 2002). This has led to
the hypothesis that Bid and Bim directly
activate Bax and Bak, while the other,
“sensitizing” BH3 proteins collude by
engaging pro-survival proteins, freeing
Bid and Bim to bind Bax and Bak (Letai
et al., 2002). Evidence for direct binding
of Bax and Bak by BH3-only proteins,
however, remains scant.
An alternative view, derived from
recent evidence that certain BH3-only
proteins target specific subsets of the
pro-survival proteins (Chen et al., 2005),
is that efficient killing requires neutraliza-
tion of multiple Bcl-2-like proteins,
because more than one pro-survival pro-
tein restrains Bak and presumably also
Bax (Willis et al., 2005). On this view, the
potency of BH3-only proteins, such as
Bim, reflects their ability to bind avidly to
each pro-survival protein, whereas the
less potent ones, like Bad, bind only a
subset. Pertinently, killing by Bad, which
binds tightly only to Bcl-2, Bcl-xL, and
Bcl-w, is enhanced by Noxa, which binds
Mcl-1 and A1 (Chen et al., 2005), and
Bad plus Noxa unleashes Bak (Willis et
al., 2005).
Thus, a plausible hypothesis for why
certain tumor cells are resistant to ABT-
737 is that they express high levels of
Mcl-1 or A1, which ABT-737 cannot neu-
tralize. If so, these tumors may be vulner-
able to a novel BH3 mimetic that binds a
different subset of Bcl-2-like proteins.
Alternatively, small molecules that down-
regulate or inhibit Mcl-1 or A1 may syner-
gize with ABT-737.
ABT-737 provides strong proof of
principle that targeting the Bcl-2 family
will have benefit in cancer therapy, and
clinical trials will be eagerly awaited. As
the Bcl-2-guarded gateway to apoptosis
appears to be the Achilles’ heel of many
tumors, BH3 mimetics with different tar-
get specificity seem destined to become
valued weapons in the oncologist’s
armamentarium. More generally, the
striking success of ABT-737 further
boosts the case (Li et al., 2004; Vassilev
et al., 2004) that small molecules can
effectively inhibit protein-protein interac-
tions, greatly expanding the universe of
potential drug targets.
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